The Juvenile Macular Degeneration (JMD) drug pipeline is advancing with promising therapies like Tinlarebant and ALK-001, targeting genetic causes to slow vision loss. https://friend24.in/blogs/36412/Juvenile-Macular-Degeneration-JMD-Drug-Pipeline-Analysis-Trend-Analysis-and